Evidence map›Paper›PMID 41728517›Full record

ArticleCureus2026

Dapsone Toxicity in Relapsing Polychondritis: Methemoglobinemia and Concomitant Hemolytic Anemia.

José Nuno Magalhães, Ana Monteiro

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

José Nuno MagalhãesMedicina, Unidade Local de Saúde de Santo António, Porto, PRT.
Ana MonteiroInternal Medicine, Unidade Local de Saúde de Santo António, Porto, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapsing polychondritis (RP) is a rare immune-mediated disorder characterized by episodic inflammation of cartilage and other proteoglycan-rich tissues. Dapsone is sometimes used as a steroid-sparing agent in selected phenotypes, but its oxidative metabolites can cause clinically significant methemoglobinemia and hemolysis. We describe a 70-year-old man with auricular chondritis and biopsy-supported RP who developed progressive dyspnea and cyanosis after three months of dapsone 100 mg daily. Oxygen saturation remained low despite supplemental oxygen, while arterial oxygen tension was preserved, prompting co-oximetry that confirmed methemoglobinemia. He improved rapidly after methylene blue administration, and dapsone discontinuation prevented recurrence. During the same admission, anemia worsened with laboratory and smear features consistent with oxidant hemolysis and a negative direct antiglobulin test, improving after drug withdrawal. This case highlights the diagnostic value of the "saturation gap" and the need to actively consider dapsone-related dyshemoglobinemia and oxidant hemolysis in patients with refractory low pulse oximetry readings or worsening anemia while on therapy, enabling timely confirmation and prompt drug withdrawal.

Indexed as

dapsone toxicitydrug-induced hemolytic anemiamethemoglobinemiarelapsing polychondritissaturation gap

Identifiers

PMID41728517
PMCPMC12919689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.